Statistics of Maintenance With Everolimus (RAD001) and Trastuzumab After Discontinuation of Chemotherapy in Heavily Pretreated HER-2+Metastatic Breast Cancer Patients: Pooled Data of Extension Cohorts of Phase Ib/II Studies